Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic (semaglutide) is an FDA-approved glucagon-like peptide-1 (GLP-1) receptor agonist designed to lower blood sugar in people with type 2 diabetes. While the medication has demonstrated significant weight loss benefits in clinical trials, it carries an official indication only for diabetes management—not weight management. However, physicians can legally prescribe medications off-label for uses not approved by the FDA, which has become a common practice for semaglutide in weight loss treatment.

FDA Approval vs. Off-Label Prescribing for Semaglutide

The FDA granted approval for Ozempic specifically to treat type 2 diabetes in 2017. Wegovy, a higher-dose formulation of the same active ingredient, received FDA approval in 2021 explicitly for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. This distinction matters because Ozempic technically lacks an official weight loss indication, despite its proven efficacy in clinical populations.

Off-label prescribing is a standard and legal medical practice in the United States. Doctors can prescribe any FDA-approved medication for any condition if they believe scientific evidence supports its use and the patient gives informed consent. Many semaglutide prescriptions for weight loss occur in this off-label context, particularly when patients have diabetes and want to address excess weight simultaneously.

Insurance coverage patterns differ between on-label and off-label uses. Many health plans cover Wegovy for weight management, yet some restrict or deny coverage for Ozempic prescribed off-label for the same purpose. This insurance inconsistency has driven patients toward compounded semaglutide options that bypass coverage barriers entirely.

How Semaglutide Works for Weight Loss

Semaglutide activates GLP-1 receptors in the brain's appetite control centers, particularly the hypothalamus. When these receptors are engaged, the hormone signals feelings of fullness and reduces hunger drive. The drug also slows gastric emptying, meaning food stays in the stomach longer and creates sustained satiety between meals.

Clinical trials demonstrate measurable weight reduction across diverse populations. In the STEP trials, participants taking semaglutide lost 10-22% of baseline body weight over 68 weeks, compared to 2-3% in the placebo groups. These results occur alongside reductions in cardiovascular risk factors, including blood pressure and cholesterol improvements independent of weight loss alone.

Individual response varies based on genetics, metabolism, and lifestyle factors. Some patients experience rapid weight loss while others see gradual, steady progress over months. PlexusDx's Precision Peptide Genetic Test identifies genetic variants in the GLP1R gene (rs6923761) and related appetite-regulation pathways, helping patients understand their likelihood of strong semaglutide response before starting treatment.

Comparing Ozempic to Compounded Semaglutide Injections

Ozempic and compounded semaglutide injections contain identical active ingredients—both deliver semaglutide via once-weekly subcutaneous injection. The primary differences lie in supply chain, regulatory oversight, and cost structure. Ozempic is manufactured by Novo Nordisk and distributed through conventional pharmaceutical channels, while compounded semaglutide is prepared by licensed 503A compounding pharmacies that must follow strict quality and sterility standards.

Compounded semaglutide from licensed 503A compounding pharmacies offers the same clinical mechanism and efficacy profile as brand Ozempic, but at substantially lower cost. PlexusDx partners exclusively with licensed 503A compounding pharmacies—never 503B facilities—and provides compounded semaglutide injections starting at $149 per month. This flat-rate pricing applies regardless of dose, with the principle that your dose may need to go up, but your price won't.

Access without insurance or membership fees represents another key advantage of compounded semaglutide through PlexusDx. The product qualifies for HSA and FSA contributions, making it accessible to uninsured patients, those with high-deductible plans, and individuals facing prior authorization delays. Patients receive treatment across all 50 states with no insurance requirement.

Safety, Side Effects, and When to Consult a Doctor

Common side effects of semaglutide include nausea, vomiting, diarrhea, and constipation—most often mild and transient during the initial dose escalation phase. Serious adverse events are rare but include pancreatitis, gallbladder complications, and diabetic retinopathy worsening in patients with pre-existing vision problems. Medical supervision ensures early detection and appropriate management of any safety concerns.

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, due to rodent studies suggesting thyroid C-cell tumors at high doses. Pregnant patients or those planning pregnancy should discontinue semaglutide, as animal data indicate potential fetal harm. Patients with severe kidney disease, heart failure, or active pancreatitis require careful evaluation before starting treatment.

PlexusDx requires a medical consultation before dispensing any compounded semaglutide. Licensed healthcare providers review medical history, current medications, and contraindications to ensure safe, appropriate treatment. Ongoing monitoring and dose adjustments happen through regular check-ins, allowing real-time assessment of efficacy and tolerability across your weight loss journey.

Cost, Accessibility, and Getting Started with PlexusDx

Brand Ozempic and Wegovy typically cost $900–$1,500 per month without insurance, with coverage subject to insurance formulary restrictions and prior authorization requirements. Wait times for pharmacy fulfillment and insurance approvals often extend treatment delays by weeks or months. PlexusDx compounded semaglutide injections eliminate these barriers with straightforward flat pricing of $149 per month for full-strength compounded injections.

PlexusDx operates without membership fees, subscription locks, or insurance dependency. Patients can cancel anytime, adjust their treatment plan as needed, and receive medications shipped directly to their home. The Precision Peptide Genetic Test ($99 add-on after the first month) maps 14 biological pathways and 49 peptides, revealing 150+ genetic insights into your appetite regulation and GLP-1 responsiveness—helping inform long-term personalization of your weight loss strategy.

Starting with PlexusDx involves a straightforward three-step process: complete an online health intake form, receive a consultation with a licensed healthcare provider who reviews your medical history and goals, and begin receiving your compounded semaglutide injections. All medications originate from licensed 503A compounding pharmacies meeting strict pharmaceutical standards. Treatment works across all 50 states, making precision weight loss accessible regardless of geography or insurance status.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can my doctor write me a prescription for Ozempic just for weight loss?

Yes, doctors can legally prescribe Ozempic off-label for weight loss under the standard practice of off-label medication use in the United States. However, insurance coverage varies and prior authorization may be required. If insurance barriers arise, PlexusDx offers compounded semaglutide injections at $149/month without insurance requirements, providing immediate access to the same active ingredient.

What's the difference between Ozempic, Wegovy, and compounded semaglutide?

Ozempic is FDA-approved for diabetes with an off-label weight loss use; Wegovy is FDA-approved specifically for weight management. Compounded semaglutide contains the identical active ingredient but is prepared by licensed 503A compounding pharmacies at lower cost ($149/month through PlexusDx). All three deliver equivalent clinical benefits through the same GLP-1 receptor activation mechanism.

Is compounded semaglutide safe, and is it as effective as brand Ozempic?

Compounded semaglutide from licensed 503A compounding pharmacies meets strict quality, sterility, and potency standards, making it clinically equivalent to brand Ozempic. Clinical efficacy is identical since the active ingredient is the same. PlexusDx partners exclusively with licensed 503A facilities and requires medical supervision for all treatments to ensure safety and appropriate dosing.

What are the main side effects I should expect with semaglutide?

Common side effects include nausea, vomiting, diarrhea, and constipation—most mild and temporary during initial dose escalation. Serious adverse events are rare but can include pancreatitis or gallbladder complications. Your PlexusDx healthcare provider monitors side effects during regular check-ins and adjusts your dose or treatment plan to maximize tolerability and weight loss results.

What does the PlexusDx Precision Peptide Genetic Test reveal about my GLP-1 response?

The Precision Peptide Genetic Test identifies 14 biological pathways and 49 peptides relevant to appetite regulation and weight loss, including key variants in the GLP1R gene (rs6923761) and other metabolic genes. These 150+ genetic insights help predict your individual likelihood of strong semaglutide response, guide personalized dosing, and inform long-term weight management strategy. The test costs $99 and is available after your first month of treatment.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves